rs121918000
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PP3_StrongPP5_Very_Strong
The NM_000478.6(ALPL):c.535G>A(p.Ala179Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000479 in 1,461,742 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 32)
Exomes 𝑓: 0.0000048 ( 0 hom. )
Consequence
ALPL
NM_000478.6 missense
NM_000478.6 missense
Scores
13
5
1
Clinical Significance
Conservation
PhyloP100: 9.55
Genes affected
ALPL (HGNC:438): (alkaline phosphatase, biomineralization associated) This gene encodes a member of the alkaline phosphatase family of proteins. There are at least four distinct but related alkaline phosphatases: intestinal, placental, placental-like, and liver/bone/kidney (tissue non-specific). The first three are located together on chromosome 2, while the tissue non-specific form is located on chromosome 1. The product of this gene is a membrane bound glycosylated enzyme that is not expressed in any particular tissue and is, therefore, referred to as the tissue-nonspecific form of the enzyme. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature enzyme. This enzyme may play a role in bone mineralization. Mutations in this gene have been linked to hypophosphatasia, a disorder that is characterized by hypercalcemia and skeletal defects. [provided by RefSeq, Oct 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.993
PP5
Variant 1-21564103-G-A is Pathogenic according to our data. Variant chr1-21564103-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 13662.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-21564103-G-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ALPL | NM_000478.6 | c.535G>A | p.Ala179Thr | missense_variant | 6/12 | ENST00000374840.8 | NP_000469.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ALPL | ENST00000374840.8 | c.535G>A | p.Ala179Thr | missense_variant | 6/12 | 1 | NM_000478.6 | ENSP00000363973 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251074Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135762
GnomAD3 exomes
AF:
AC:
3
AN:
251074
Hom.:
AF XY:
AC XY:
3
AN XY:
135762
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000479 AC: 7AN: 1461742Hom.: 0 Cov.: 32 AF XY: 0.00000825 AC XY: 6AN XY: 727192
GnomAD4 exome
AF:
AC:
7
AN:
1461742
Hom.:
Cov.:
32
AF XY:
AC XY:
6
AN XY:
727192
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 05, 2023 | Identified in patients with childhood hypophophatasia who harbored a second ALPL variant of unknown phase in published literature (Whyte et al., 2015; Genest et al., 2018); Reported in a heterozygous adult patient with features of hypophosphatasia in published literature (Schmidt et al., 2019); Published functional studies demonstrate a damaging effect on protein trafficking and enzyme activity (Weiss et al., 1988; Shibata et al., 1998; Di Mauro et al., 2002; Zhu et al., 2012); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Also denoted as A162T due to alternative nomenclature; This variant is associated with the following publications: (PMID: 23509830, 9562633, 28991257, 23791648, 31400546, 3174660, 12162492, 11438998, 25731960, 29774402, 31485555, 32368696, 32160374) - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Oct 01, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jan 06, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 15, 2023 | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects ALPL function (PMID: 9562633, 12162492, 23509830, 32160374). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ALPL protein function. ClinVar contains an entry for this variant (Variation ID: 13662). This variant is also known as Ala162Thr. This missense change has been observed in individual(s) with clinical features of hypophosphatasia (PMID: 3174660, 11438998, 32160374; Invitae). This variant is present in population databases (rs121918000, gnomAD 0.003%). This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 179 of the ALPL protein (p.Ala179Thr). - |
Infantile hypophosphatasia Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 30, 2024 | - - |
Likely pathogenic, criteria provided, single submitter | literature only | Counsyl | Aug 01, 2014 | - - |
Hypophosphatasia Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 24, 2021 | Variant summary: ALPL c.535G>A (p.Ala179Thr) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 251074 control chromosomes (gnomAD). c.535G>A has been reported in the literature in multiple compound heterozygous and homozygous individuals affected with Hypophosphatasia (e.g. Weiss_1988, Taillandier_2001, Whyte_2015, Seefried_2017, Del Angel_2020). These data indicate that the variant is very likely to be associated with disease. Experimental evidence obtained from multiple functional studies, demonstrated the variant causes a severe reduction in enzyme activity and affects its stability, transport and mineralisation ability (e.g. Weiss_1988, Fedde_1996, Di Mauro_2002, Zhu_2012, Del Angel_2020). A ClinVar submitter (evaluation after 2014) cites the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Aug 25, 2020 | - - |
Childhood hypophosphatasia;C0268412:Infantile hypophosphatasia;C0268413:Adult hypophosphatasia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 26, 2022 | - - |
Adult hypophosphatasia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 14, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
D;.;.;D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
.;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
H;.;.;H
MutationTaster
Benign
A;A;A;A;A
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;D;D;D
REVEL
Pathogenic
Sift
Uncertain
D;D;D;D
Sift4G
Uncertain
D;D;D;D
Polyphen
P;.;.;P
Vest4
MutPred
Gain of glycosylation at A179 (P = 0.0474);.;.;Gain of glycosylation at A179 (P = 0.0474);
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at